...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Comparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbits.
【24h】

Comparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbits.

机译:脂质复合的两性霉素B和脂质体的两性霉素B对兔球虫性脑膜炎的比较疗效。

获取原文
获取原文并翻译 | 示例

摘要

In separate previous studies, we have shown that lipid-complexed amphotericin B (Abelcet [ABLC]) and liposomal amphotericin B (AmBisome [AmBi]) are efficacious against coccidioidal meningitis in rabbits. Here, we compared ABLC and AmBi directly in a coccidioidal meningitis model. Male New Zealand White rabbits were infected with 5 x 10(4) Coccidioides posadasii arthroconidia by direct cisternal puncture. Therapy with intravenous ABLC or AmBi at 7.5 or 15 mg/kg of body weight or sterile 5% dextrose water (D5W) began 5 days later. Clinical assessments were done daily; cerebrospinal fluid and blood samples were obtained on day 15 and upon euthanasia. Survivors to day 25 were euthanatized, the numbers of CFU in their tissues were determined, and histology analyses of the brains and spinal cords were done. Controls showed progressive disease, whereas animals treated with either dose of either drug showed few clinical signs of infection. All ABLC- or AmBi-treated rabbits survived, whereas eight of nine D5W-treated rabbits were euthanatized before day 25 (P < 0.0001). Numbers of CFU in the brains and spinal cords of ABLC- or AmBi-treated animals were 100- to 10,000-fold lower than those in the corresponding tissues of D5W-treated animals (P < 0.0006 to 0.0001). However, only two or fewer given a regimen of ABLC or AmBi were cured of infection in both tissues. Fewer ABLC-treated rabbits (four of eight treated with 7.5 mg/kg and five of eight treated with 15 mg/kg) than controls (nine of nine) had meningitis at any level of severity (P, 0.015 or 0.043 for animals treated with ABLC at 7.5 or 15 mg/kg, respectively). Although groups of rabbits treated with AmBi regimens did not have significantly fewer animals with meningitis than the control group (P > 0.05), ABLC and AmBi were not significantly different. In this model, intravenous ABLC and AmBi were similarly highly effective, with few clinical signs of infection, 100% survival, and significantly reduced fungal burdens among treated animals. There appeared to be little benefit in using the 15-mg/kg dosage of either formulation. There was no significant advantage of one drug over the other for this indication. Further studies are required to determine the lowest effective doses of these formulations.
机译:在单独的先前研究中,我们显示了脂质复合的两性霉素B(Abelcet [ABLC])和脂质体的两性霉素B(AmBisome [AmBi])对兔球虫性脑膜炎有效。在这里,我们直接在球菌性脑膜炎模型中比较了ABLC和AmBi。雄性新西兰白兔通过直接的胸骨穿刺术感染了5 x 10(4)球孢子虫。 5天后开始用7.5或15 mg / kg体重的静脉内ABLC或AmBi或无菌5%葡萄糖水(D5W)进行治疗。每天进行临床评估;第15天和安乐死时获得脑脊液和血液样品。对第25天的幸存者实施安乐死,确定其组织中CFU的数量,并对大脑和脊髓进行组织学分析。对照组显示出进行性疾病,而用任一种剂量的任一种药物治疗的动物均未见临床感染迹象。所有用ABLC或AmBi治疗的兔子均存活,而在用D5W治疗的9只兔子中,有25只在第25天前被安乐死(P <0.0001)。 ABLC或AmBi处理的动物的大脑和脊髓中CFU的数量比D5W处理的动物的相应组织中的CFU数量低100到10,000倍(P <0.0006至0.0001)。然而,只有两种或两种以下的ABLC或AmBi方案可以治愈两种组织的感染。接受ABLC治疗的兔子(在接受LVmg处理的动物中,在任何严重程度下,脑膜炎的发生率均低于对照组(九只动物中的九只),八只动物中的五只以15 mg / kg处理)中的五只(P,0.015或0.043) ABLC分别为7.5或15 mg / kg)。尽管用AmBi方案治疗的兔子组的脑膜炎动物没有明显少于对照组(P> 0.05),但ABLC和AmBi并没有显着差异。在该模型中,静脉内ABLC和AmBi同样有效,几乎没有感染的临床征象,存活率100%,并且大大减轻了治疗动物的真菌负担。使用两种制剂的15 mg / kg剂量似乎没有什么好处。对于这种适应症,一种药物与另一种药物相比没有显着优势。需要进一步的研究以确定这些制剂的最低有效剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号